Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-Guided P2Y12 Inhibitor Selection in Symptomatic ICAD (NUANCE-ICAD)
NCT06714526Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ticagrelor in intracranial atherosclerosis (ICAD) and ischemic stroke (2 arms), sponsored by Sunnybrook Health Sciences Centre. Primary endpoints: Rate of recruitment at 90 days, Rate of study completion at 90 days and 4 more. Started Oct 2025; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
intracranial atherosclerosis (ICAD)ischemic stroke
Beyond the preview
Go deeper on NCT06714526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714526.